We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.34B
AUM Growth
-$123M
Cap. Flow
-$153M
Cap. Flow %
-11.43%
Top 10 Hldgs %
26.37%
Holding
215
New
22
Increased
46
Reduced
51
Closed
31

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$30.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$21.3M
3
BWXT icon
BWX Technologies
BWXT
+$17.1M
4
CBAY
Cymabay Therapeutics
CBAY
+$15.2M
5
IMGN
Immunogen Inc
IMGN
+$14M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$37.8M
2
INSP icon
Inspire Medical Systems
INSP
+$37.4M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$35.7M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$19.3M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 52.08%
2 Technology 13.86%
3 Industrials 8.87%
4 Energy 5.36%
5 Financials 5.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
176
DELISTED
WW International
WW
– –
-137,750
Closed -$926K
HCCI
177
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
– –
-57,860
Closed -$2.19M
KDNY
178
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-928,637
Closed -$35.7M
DICE
179
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-416,151
Closed -$19.3M
DALS
180
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
– –
-200,000
Closed -$2.05M
ISEE
181
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-325,548
Closed -$12.8M
4 5 6 7
8

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Nicholas Investment Partners held 215 positions worth $1.34B, down 8.4% from $1.46B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Nicholas Investment Partners withdrew a net $153M in Q3 2023, closing 31 positions and reducing 51 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $37.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Sarepta Therapeutics worth $22.8M.

  • Nicholas Investment Partners's largest Q3 2023 buy was Sarepta Therapeutics: 188,085 shares worth $22.8M.
  • Nicholas Investment Partners added most to Immunocore in Q3 2023, an estimated $30.1M increase.
  • Nicholas Investment Partners's biggest Q3 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $12M.
  • Nicholas Investment Partners fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $37.8M.
  • Nicholas Investment Partners's ten largest holdings make up 26% of its $1.34B portfolio in Q3 2023.
  • Nicholas Investment Partners opened 22 new positions and closed 31 in Q3 2023.
  • Nicholas Investment Partners's portfolio value fell 8.4% quarter-over-quarter to $1.34B.

Based on Nicholas Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.